StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank:
Power Rank trend -> Rising
06/13/2025 16:01:00 EST
CytomX Therapeutics Inc (CTMX)
Industry: Biotechnology
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, CTMX has been trading in a range between $2.70 and $2.03 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
CTMX is breaking above top of the recent 20 day range at $2.70 and appears that it could have some more upside. If it enters a yellow zone the trend may be faltering - consider exiting or taking profits. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
CytomX Therapeutics Inc $CTMX entered a Green zone 38 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $4.75, a potential upside of 72.73% from the recent price of 2.75. The stock is trading 12.73% (potential upside) below its 52 week high of $3.10 and 587.5 % (potential downside) above its 52 week low of $0.40 - based on the recent price.
Company Summary
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.
News
| CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 2:35 p.m. ET. Source: GlobeNewsWire Thu, 29 May 2025 08:00:00 -0400 Sentiment: Neutral |
| CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the first patient has been dosed with CX-801 in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in the ongoing Phase 1 dose escalation study (NCT06462794) evaluating safety and initial clinical activity in patients with metastatic melanoma. Source: GlobeNewsWire Mon, 19 May 2025 08:00:00 -0400 Sentiment: Neutral |
| CytomX Therapeutics: Doubling Overnight On Phase 1 Data CytomX Therapeutics' CX-2501 shows promising phase 1 results in refractory colorectal cancer, with a 27.8% objective response rate and manageable toxicity. CTMX's financial position strengthened by a $100 million stock offering, extending cash runway through 2025. CX-904 development with Amgen discontinued, but collaboration continues on a preclinical T-cell engager project. Source: Seeking Alpha Tue, 13 May 2025 10:34:54 -0400 Sentiment: Positive |
| CytomX Therapeutics, Inc. (CTMX) CX-2051 Phase 1 Interim Clinical Data Call (Transcript) CytomX Therapeutics, Inc. (NASDAQ:CTMX ) CX-2051 Phase 1 Interim Clinical Data in Advanced Colorectal Cancer May 12, 2025 8:00 AM ET Company Participants Sean McCarthy - Chairman and CEO Chris Ogden - CFO Wayne Chu - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Anupam Rama - JPMorgan Peter Lawson - Barclays Robert Driscoll - Wedbush Securities Daniel Smith - H.C. Wainwright Operator Good morning, everyone, and thank you for standing by. Source: Seeking Alpha Mon, 12 May 2025 14:40:28 -0400 Sentiment: Neutral |
| Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report CytomX Therapeutics, Inc.‘s CTMX share price was up 94.46% at last check on Monday. Source: Benzinga Mon, 12 May 2025 11:11:40 -0400 Sentiment: Positive |
Technicals 52 Week Hi: 3.095 52 Week Low: 0.4 Beta: 2.12 50 Day MA: 1.5226 200 Day MA: 1.1077 Earnings / Revenue Trends Qtr Earnings Growth YOY: 0.606 Qtr Revenue Growth YOY: 0.228 Forward PE: 8.3333 Trailing PE: 5.7292